US EditionPublished • loading... • Updated
Canadian researchers reach 'major milestone' in search for ALS treatment
- On May 7, 2025, Canadian researchers at Sunnybrook Health Sciences Centre started a Phase 1 trial delivering drugs via ultrasound to six ALS patients, including Bill Traynor.
- The trial addresses the blood-brain barrier, which blocks drug access despite drugs potentially treating ALS, a fatal neurodegenerative disease with no cure.
- Traynor received immunoglobulin, an antibody therapy that suppresses inflammation, delivered precisely to his motor cortex using focused ultrasound, temporarily opening the barrier.
- Researchers confirmed the immunoglobulin crossed to the target area and Traynor tolerated the procedure well, though they cautioned the trial is early-stage and not expected to produce treatments.
- Investigators called this a major milestone enabling future drug testing to target ALS, and Traynor views the study as a source of hope despite his terminal diagnosis.
Insights by Ground AI
9 Articles
9 Articles
Canadian Researchers Reach ‘Major Milestone’ in Search for ALS Treatment
Standing in an MRI control room packed with fellow ALS researchers, Dr. Lorne Zinman excitedly points to the brain scan on his phone. There’s a white spot on the image, right where Bill Traynor’s motor cortex is. The 70-year-old patient is lying on the MRI bed with his head inside a dome that sends focused ultrasound waves to his head in the experimental trial. The white spot signals that the immunoglobulin Traynor received intravenously has cro…
·New York, United States
Read Full Article
Winnipeg Free Press+4 Reposted by 4 other sources
Canadian researchers reach 'major milestone' in search for ALS treatment
Breaking News, Sports, Manitoba, Canada
·Winnipeg, Canada
Read Full Article
Coverage Details
Total News Sources9
Leaning Left3Leaning Right1Center2Last UpdatedBias Distribution50% Left
Bias Distribution
- 50% of the sources lean Left
50% Left
L 50%
C 33%
R 17%
Factuality
To view factuality data please Upgrade to Premium
